Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer

NANot yet recruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

March 1, 2025

Study Completion Date

March 1, 2028

Conditions
Oligometastatic Prostate Carcinoma
Interventions
DRUG

ADT combined with abiraterone

The patients will receive long-term ADT combined with abiraterone.

RADIATION

neoadjuvant hormone and RT

The patients will receive 1 month of naADT, followed by metastasis-directed radiation and abdominal or pelvic radiotherapy. Then, radical prostatectomy will be performed at intervals of 5-15 weeks after radiotherapy, and long-term ADT will be continued.

Trial Locations (6)

200003

The Second Affiliated Hospital of Naval Medical University, Shanghai

200433

The First Affiliated Hospital of Naval Medical University, Shanghai

210009

Jiangnan University Medical Center, Wuxi

510120

the First Affiliated Hospital of Guangzhou Medical University, Guangzhou

Unknown

First Affiliated Hospital and Medical College of Soochow University, Suzhou

The First Affiliated Hospital of Ningbo University, Ningbo

All Listed Sponsors
lead

Changhai Hospital

OTHER

NCT05707468 - Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer | Biotech Hunter | Biotech Hunter